IGI Laboratories to Present at 25th Annual ROTH Capital Conference on March 20, 2013

25th Annual ROTH Conference

BUENA, N.J.--()--IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based topical generic drug development and manufacturing company, will be presenting at the 25th Annual ROTH Conference. The Conference will take place on March 17-20, 2013 at the Ritz-Carlton in Dana Point, California.

Jason Grenfell-Gardner, CEO and President and Jenniffer Collins, Chief Financial Officer of IGI Laboratories, Inc. will present on Wednesday March 20, 2013 at 9:00 a.m. PT / 12:00 p.m. ET. Investors attending the conferences who wish to meet with Mr. Grenfell-Gardner and Mrs. Collins for a one-on-one meeting should contact their ROTH Capital representative directly.

The presentation will be webcast and will be accessible online on the Investors section of the Company's website at http://www.igilabs.com. A replay will be available for 90 days.

About IGI Laboratories, Inc.

IGI Laboratories is a developer and manufacturer of topical formulations for the pharmaceutical, OTC, and cosmetic markets. Our mission is to be a leading player in the generic topical prescription drug market.

Forward-Looking Statements

IGI Laboratories, Inc. “Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995. This press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, plans, objectives, expectations and intentions, and other statements contained in this press release that are not historical facts and statements identified by words such as " will," "possible," "one time," "provides an opportunity," "continue" or words of similar meaning. These statements are based on our current beliefs or expectations and are inherently subject to various risks and uncertainties, including those set forth under the caption "Risk Factors" in IGI Laboratories, Inc.’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q as filed with the Securities and Exchange Commission. Actual results may differ materially from these expectations due to changes in global political, economic, business, competitive, market and regulatory factors or IGI Laboratories, Inc.’s ability to implement business strategies. IGI Laboratories, Inc. does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

Contacts

IGI Laboratories, Inc.
Jenniffer Collins, 856-697-1441
www.igilabs.com

IGI Laboratories, Inc.